New insider activity at Insmed ( (INSM) ) has taken place on August 14, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Melvin Sharoky recently sold 10,000 shares of Insmed stock, amounting to a significant transaction valued at $1,215,800.
Recent Updates on INSM stock
In the last 24 hours, Insmed’s stock developments have been influenced by several key factors. Morgan Stanley downgraded Insmed to Equal Weight from Overweight, citing that the current valuation already reflects the near-term opportunity of its newly approved drug, Brinsupri, despite its “clean” label and promising launch preparations. The approval of Brinsupri has generally been seen as a positive development, with Wells Fargo and RBC Capital increasing their price targets, driven by the drug’s strategic pricing and market potential. Insmed’s recent Q2 earnings call highlighted strong performances across its late-stage and early-stage portfolios, with record ARIKAYCE revenue and successful capital raising efforts, although concerns remain about the launch challenges for brensocatib and uncertainties in certain trials. The company is well-positioned for future growth, with significant clinical and commercial milestones anticipated in the coming year.
Spark’s Take on INSM Stock
According to Spark, TipRanks’ AI Analyst, INSM is a Neutral.
Insmed’s overall stock score is primarily impacted by its weak financial performance and valuation challenges. However, positive earnings call sentiment and significant corporate events provide some optimism for future growth.
To see Spark’s full report on INSM stock, click here.
More about Insmed
YTD Price Performance: 75.65%
Average Trading Volume: 3,809,128
Technical Sentiment Signal: Buy
Current Market Cap: $25.79B